Healthcare / BiotechnologyNasdaqCM
$4.84
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
3/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$8M
P/E
N/A
•EV/EBITDA
N/A
•ROE
164.7%
↑Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-59.6M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | — | — | — | — | — | $300000.00 | — | — |
| Net Income | $-59.6M | $-59.6M | $-69.8M | $-123.5M | $-106.5M | $-95.4M | $-35.9M | $-29.9M |
| EBITDA | $-58.9M | $-58.9M | $-73.0M | $-128.5M | $-106.9M | $-95.1M | $-29.1M | $-27.4M |
| EPS | -1.01 | -1.01 | -1.44 | -2.58 | -2.74 | -2.76 | — | — |
| Operating Margin | — | — | — | — | — | -32146.7% | — | — |
| Net Margin | — | — | — | — | — | -31800.7% | — | — |
| Returns | ||||||||
| ROE | 164.7% | 164.7% | -489.1% | -174.7% | -59.0% | -45.3% | -17.1% | — |
| Growth & Yield | ||||||||
| EPS Growth | 29.9% | 29.9% | 44.2% | 5.8% | 0.7% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.